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Abstract: We aimed to find clinically relevant gene activities ruled by the signal transducer and activator of transcription 3 (STAT3) 
proteins in an ER(-) breast cancer population via network approach. STAT3 is negatively associated with both lymph nodal category 
and stage. MYC is a component of STAT3 network. MYC and STAT3 may co-regulate gene expressions for Warburg effect, stem cell 
like phenotype, cell proliferation and angiogenesis. We identified a STAT3 network in silico showing its ability in predicting its target 
gene expressions primarily for specific tumor subtype, tumor progression, treatment options and prognostic features. The aberrant 
expressions of MYC and STAT3 are enriched in triple negatives (TN). They promote histological grade, vascularity, metastasis and 
tumor anti-apoptotic activities. VEGFA, STAT3, FOXM1 and METAP2 are druggable targets. High levels of METAP2, MMP7, IGF2 and 
IGF2R are unfavorable prognostic factors. STAT3 is an inferred center regulator at early cancer development predominantly in TN.
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Introduction
Cancer is one of the major killing diseases   worldwide. 
Among them, breast cancer (BC) has quickly become 
the most commonly diagnosed malignancy of women 
in Taiwan during the past decade.1 Such a global dis-
ease has its own heterogeneity clinically and molecu-
larly. Up to now, ER(-) breast cancer population still 
needs as many efficient therapies as ER(+) one has. 
The  poor  prognostic  features  for  both  triple  nega-
tives (TN) and ERBB2+ have been considered as the 
top two killing subtypes in breast cancer.2 A recent 
review on TN tumors3 pointed out that TN is a het-
erogeneous group of multiple molecular subtypes of 
breast cancer.
To resolve the complexity of disease like cancer 
using systems approaches, which have integrated tran-
scriptomic data into molecular network, they show 
promise in their ability to classify tumor subtypes, 
predict  clinical  progression,  and  inform  treatment 
options.4,5 We proposed to search for the transcrip-
tion factors critical to a subset of ER(-) breast tumor 
development  with  the  aid  from  the  new  statistical 
approach6 on analyzing genome-wide gene expres-
sion data of 91 infiltrating ductal carcinoma (IDCs).
Many  transcription  factors  have  been  predicted 
to  be  determinants  of  clinical  indices  in  91  IDCs. 
Their clinical niches are under investigation. In this 
study, we are interested in unraveling the role(s) for 
the  most  recognized  signal  transduction  pathways 
in both mammary gland and breast cancer develop-
ment involving the STAT3 protein,7–10 which is a tran-
scription factor (TF). The Stat family of transcription 
factors is known to have diverse roles in mammary 
gland development.7 STAT3 is widely overexpressed 
in breast cancers.11 It has been classified as a proto-
  oncogene8 and suggested as a therapeutic target of 
cancers in model systems.12 Up to now, roles of STAT3 
in  clinical  breast  cancer  population  study  remain 
either  controversial  or  not  completely  understood. 
For instance, the prognostic value of STAT3 in human 
breast cancer remains controversial and associations 
range  from  favorable  to  unfavorable.13  We  revisit 
this research topic because we noticed an elevated 
expression of STAT3 in triple negatives as compared 
to that in ERBB2+ in the cohort (77A). This could 
be subtype enriched transcriptional activities in caus-
ing unique pathological phenotypes. We would like to 
use this established method of ours—CIDUGPCC to 
unravel the potential network activities of STAT3 in a 
subtype enriched manner. Network medicine may be 
desirable in future medicine.14,15
Here,  we  proposed  the  diagnostic  and/or  prog-
nostic roles of STAT3 transcriptional regulatory net-
work to be predicted at a global transcriptome scale 
in a clinical breast cancer population. Furthermore, 
the annotated gene activities of STAT3 subnetworks 
will be supported by inferred biochemical pathways, 
patients  diagnostic  result(s),  clinical  outcome  and 
published research evidence by others.
Materials and Methods
Features of surgical specimens in 103 
breast cancer gene expression profiles
We  obtained  91  specimens  of  primary  infiltrat-
ing ductal carcinoma of breast (IDC) consisting of 
five  subgroups.  They  are  triple  negatives(48/91), 
ERBB2+(29/91), ER(-)PR(+)HER(-)(5/91), ER(-)
PR(+)HER(+)(6/91)  and  ER(-)PR(+)  but  HER(?)
(3/91). Five specimens for metaplastic carcinoma of 
breast (MCB) were included in this study. Seven non-
tumor samples were surgically taken from breast tis-
sue adjacent to some of 91 ER(-) IDC breast tumors 
as  a  control.  Those  samples  were  obtained  from 
patients who underwent surgery at National Taiwan 
University  Hospital  (NTUH)  between  1998  and 
2007. Breast cancer samples containing relatively 
pure cancer as defined by greater than 50% tumor 
cells per high-power field examined in an adjacent 
section  of  tumor  sample  are  for  this  study.16 All 
patients had given informed consent according to 
the guidelines approved by the Institutional Review 
Board at NTUH. Total dataset for 103 gene expres-
sion  profiles  (103A)  used  in  this  study  has  been 
submitted to NCBI-GEO. Its accession number is 
GSE32641. Both TN and ERBB2+ are major sub-
populations among four subtypes of ER(-) breast 
cancer cohort. In addition, the mRNA levels of both 
STAT3 and MYC are elevated in TN but are in low 
expression mode in ERBB2+ (Fig. 3). We decided 
to only pick up those two subtypes of ER(-) IDCs 
(77 IDCs) for entire network study to control the 
confounder from a small number (N = 14A) of other 
subtypes in 91 IDCs. However, some comparisons 
were made among 91 IDCs, 5 MCBs and 77 IDCs 
in this study.malignant phenotypes regulated by STAT3
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Immunohistochemical (IHC) stain of 
paraffin-embedded breast cancer slides
A  standard  biotin-streptavidin-peroxidase  procedure 
with  automated  IHC  systems  (Benchmark,  Ventana 
Medical Systems, USA) was used. For visualization of 
immunostain, we applied diaminobenzidine as a chro-
mogen (i view™ DAB Detection Kit, Ventana Medical 
Systems, USA). The primary antibodies described inside 
parentheses were used for detection of ERα (ER-SP1, 
Ventana  Medical  Systems,  Inc., Tucson, AZ,  USA), 
PR  (PGR-5D10,  Abnova,  Taipei  City,  Taiwan)  and 
ERBB2 (polyclonal antibody against human c-erbB2 
antigen, Dako Cytomation, Denmark) (dilution ratio at 
1:800), respectively. The final IHC stains of ER, PR and 
ERBB2 (HER) on slides were examined by two experi-
enced pathologists (SMJ and HCL). For ERBB2 (IHC 
score: 2+), determination of Her-2/neu gene copy num-
ber by chromogenic in situ hybridization (CISH) was 
performed (Figs. 4A and B). The CISH study results 
were evaluated with a regular light microscope (Nikon 
E600) and they were counted by a pathologist (SFH).17
A noninvasive vascularity detection  
in vivo and baseline characteristics  
of the studied patients
Mammography has been the mainstay of breast cancer 
screening worldwide. It can detect the microcalcifica-
tion in breast lesions for stage 0 breast cancer patients. 
However, microcalcification in breast lesion is difficult 
to be detected by mammography for Asian women 
as  compared  to  Caucasian  women.   Alternatively,  a 
noninvasive Doppler ultrasound has been applied for 
breast cancer screening in Asian women population 
(e.g. Taiwanese women) who have the morphological 
view of breast tissue denser than those of Caucasian 
women.18 Both vascular patterns and vascular density 
are  quantitatively  measured  in  tumor  section  using 
this  technique  in  coupling  with  a  computed  image 
processing system, which automatically calculate the 
density of vascular signals (designated as “vascular-
ity index”) within the tumor tissue of interest.19 Vas-
cularity index (VI) measures both microvasculature 
and  macrovasculature  at  once.  In  particular,  color 
Doppler ultrasound was reported to be able to depict 
larger vessels of approximately 100 m or larger in 
diameter in vivo.20,21 Clinically, the in situ detection 
of  biochemical  activity  for  a    sonogram  of  interest 
via  immunohistochemistry  reveals  the  remodeling 
vascularity in tumor section may be traced by sono-
grams. The angiosonograms are in vivo evidence of 
angiogenesis. The performance for detecting angio-
genesis activities of breast tumors using color Doppler 
ultrasound that now is routinely used at NTUH. We 
have gathered some angiosonograms for patients in 
this study. The following clinical variables were stud-
ied: ER, PR, HER, lymphovascular invasion (LVI), 
lymph node metastasis (LYM), number of lymph node 
positive (LNM), age (years: ,48 or .48), tumor size 
(in centimeters), histological grade (including nuclear 
pleomorphism (NP), mitotic count (MC) and tubule 
formation (TF)) and clinical stage (Table 2).
microarray data analyses
A gene profile per breast tumor specimen was ana-
lyzed using Human 1A (version 2) oligonucleotide 
microarray (half a genome size: 22k).16 We used a new 
measure of association called coefficient of intrinsic 
dependence (CID) in combination with   Galton Pear-
son’s  Correlation  Coefficient  (GPCC)  to  analyze 
the  continuous  variables  (e.g.  the  gene  expression 
profiles)  genome-wide.  We  built  a  transcriptional 
regulatory  network  by  performing  the  analysis  of 
CID-TFUGPCC  (Fig.  1).  The  brief  flow  of  entire 
analyses involving the CID procedure explains how 
those get extended in this study (Fig. 2).
The  correlation  between  the  mRNA  level  of  a 
selected TF and the clinical index was analyzed by 
applying analysis of variance (ANOVA) to dichoto-
mous  and  multichotomous  indices,  respectively.22 
We, therefore, selected the clinical significant sub-
populations for network approach using the analysis 
of CID-TFUGPCC.
CID has the advantage of identifying indirect (or 
non-linear) regulatory association between a TF and 
its target gene. On the other hand, GPCC preferen-
tially identifies direct (or linear) regulatory association 
between a TF and its target gene. Thus, it is neces-
sary to combine both unique regulatory actions of a 
TF on its target gene to construct a TF mediated tran-
scriptional regulatory network. The rationale of using 
both methods together has been described in Liu et al. 
(2009).6 In this study, we use hierarchical   clustering23 
to subgroup data before CID measurements that is 
to replace quantile clustering described previously.6 
It  is  the  key  clustering  strategy  in  mimicking  a Liu et al
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pre-programmed transcriptional activity mediated by 
a selected TF to be clustered into a subgroup for CID 
analysis. We also take advantage of a unique feature 
of CID in measuring the association for a small N in 
each subgroup (N ≈10). After hierarchical clustering 
on the data in a given sample population, we set the 
final number of subgroups to be rounding number for 
1/10th the total sample number (i.e. 8 subgroups for 
77A) before CID measurement. The mRNA data par-
titioning for a perturbed transcription factor in a given 
population may be clustered based on the similar gene 
expression patterns. Only some unique situations may 
need other clustering strategies24 before CID measure-
ment. We evaluate significance (P % 0.05) of both 
statistical measurements. If either one or both show 
significance, we point arrows from the TF toward its 
predicted target gene pool to form a network (Fig. 1).
We  used  Gene  Spring  GX7.3.1  (Agilent 
  Technologies, USA) for generating Venn Diagrams. 
This analysis allows gene pools to be extracted from 
overlapped  network  and/or  non-overlapped  ones 
when two networks of interest are compared. In addi-
tion, for biochemical pathway profiling of a selected 
transcriptional regulatory network, we included gene 
pools in the signal transduction pathways from both 
KEGG  and  NCBI  databases  to  be  compared  with 
The mRNA levels of a
gene in a selected
population
The mRNA levels of TF
in a selected
population
Subgrouping by
one-dimensional
hierarchical
clustering
GPCC CID-TF
GPCC signifcant or
CID-TF significant
CID-TFUGPCC
Figure  1.  The  core  methodology  of  CId-TFUGpCC. A  procedure  for 
producing  a  transcriptional  regulatory  network  of  interest  in  silico  via 
performing  the  combined  method—CIdUGpCC  is  presented  as  fol-
lows. A selected dataset, which contains gene expression profiles of a 
population with mixed categories of interest, was chosen for study. The 
mRNA levels of a selected transcription factor in the given dataset were 
analyzed by the combined statistical measures (i.e. CId and GpCC) to 
produce 22 possible sets of results. Before CId measurement, a cluster-
ing strategy is applied to divide a pool of data, which contains different 
mRNA levels of a TF, into several subpools based on the similarity in 
mRNA expression patterns of the TF within each subpool. 
notes: The statistically identified target gene of a TF is determined by 
either significance (P % 0.05) in CId-TF or in GpCC. “TF” stands for a 
transcription factor.
Given a TF of interest
ANOVA
Selection of
clinical
significant
subpopultation
CID-TFUGPCC
Significant gene pools for TF-target
networks
Venn Diagram
Probe annotation
Gene pools extracted from
overlapped network and/or non-
overlapped network
Functional prediction and
validation
Figure 2. The flow chart of steps involved in establishing the transcrip-
tional regulatory network in relation to biochemical phenotypes, malig-
nant phenotypes and clinical outcomes. A self-contained summary of the 
CId procedure is presented. A major scheme (linked by dark arrows) 
includes (1) ANoVA test on a TF of interest against seven clinical indi-
ces; (2) CId-TFUGpCC analyses on a selected population based on its 
significant features evaluated by ANOVA; (3) Venn Diagram analysis on 
the selected gene pools (networks) from the results of step (2); (4) Func-
tional validation of a subnetwork of interest derived from step (3) by its 
gene expression patterns in different clinical indices, by its prediction in 
clinicopathological features and by its supporting literature documenta-
tion. A side scheme (linked by light arrows) is based on the same dataset 
but using a different TF to carry on steps (2)–(4).malignant phenotypes regulated by STAT3
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those in the network. We also evaluated the common 
gene pools shared by network and clinicopathological 
parameter(s). Based on current version of gene anno-
tation from NCBI database, we were able to do func-
tional prediction on gene lists in subnetworks within the 
selected network. We demonstrated gene expression 
patterns of those subnetworks in heatmaps along with 
(1) their relevant clinical categories; (2) their predic-
tion power for the new clinicopathological feature(s); 
and (3) their supporting literature documentation to 
further functionally validate network results.
The  heatmaps  showing  gene  expression  pat-
terns were displayed after unsupervised hierarchical 
  clustering. Three steps are included as follows. First, 
the log2 ratio for each gene was first centered by sub-
tracting the mean across all samples to discriminate the 
subclass of the dataset. Then, the selected gene expres-
sion profiles were fed into software for displaying gene 
list (Y axis) and patient arrays (X axis) based on unsu-
pervised hierarchical clustering analysis on gene pro-
files of selected arrays. Lastly, to generate feature color 
bars underneath of the heatmap, we only locate each 
feature of interest based on the final heatmap display.
We evaluated the significance (P % 0.05) for a time 
course changes in the number of survival cases after 
surgical removal of tumor parts in two patient groups 
by Kaplan-Meier curves of overall survival.25 Those 
two groups were split from a given population based 
on their mRNA expression levels of a probe of interest 
(i.e. the ranking status for high expression levels of a 
selected probe in a group is at top 10% of the given 
population as compared to that in another group.) or 
were two selected patient groups based on their distinct 
features.25 Those two selected patient groups have fol-
low-up data extending for less than 20 year period.
Computing P-values for results from 
univariate CId and GpCC analyses
The univariate CID result for a given TF was designated 
as CID-TF. Instead of all subgroups having an equal 
size (N ≈ 10),2 we divided the cohort by hierarchical 
clustering23 (described in method as above) to mimic 
biological systems in which similar expression pattern 
in a subgroup may reflect the similar biological event 
shared by the members within a subgroup. The subgroup 
was designated as j. For instance, each subCID value 
of the assigned subgroup (  j) is determined in part by 
the sample size of the subgroup j, a constant value and 
the two times square of difference between cumulative 
distribution function (CDF) of the mRNA levels for a 
gene Y in the subgroup j and the average CDF of the 
mRNA levels for a gene Y in a given   population. Gene 
Y stands for a potential target gene of a TF of interest. 
Total CID value demonstrates the degree of dependence 
between a TF and its target gene.6
To access the significance of univariate CID values 
generated via in silico analyses and to facilitate com-
parison  among  data  derived  from  different  types  of 
methods, the univariate CID value, S, was compared 
with the values generated by random sampling mim-
icking  the  data  distribution  of  gene  Y  that  is  inde-
pendent  on  the  data  partitioning  of  an  assigned TF. 
In 77A study, the independent data distribution was 
derived from randomly drawing 77 simulated values 
for an artificial gene and put the appropriate number 
of data for this gene in each subgroup that is the same 
as the sample size in each pre-clustered subgroup. We 
re-computed the subCID value of each subgroup and 
added them together to be a new CID value (K). This 
was repeated 1,000 times and yields 1,000 of CID val-
ues (Ki, i = 1–1,000). The P value was determined by 
an equation (i.e. P = (1+ N(ki ^ S))/1,001, where N(ki ^ S) is 
the number of Ki values greater than S). The P values 
for GPCC measurements were computed using asymp-
totic normal theory.26 We set the cut off point for P value 
of both methods to be significant when P % 0.05.
Results and Discussion
STAT3 is critical to ER(-) breast  
tumor development
CID-STAT3UGPCC  pulls  a  gene  pool  containing 
potential target genes of STAT3. Based on current ver-
sion of functional annotation for each potential target 
gene of STAT3 (NCBI database), we have only observed 
a few cancer related activities described in the text 
below. Most of those genes are shared determinants 
of seven clinical categories. The global pathophysi-
ological activities of STAT3 are not visible because the 
limiting factor (i.e. each gene expression profile per 
tumor sample containing half a genome size of probes 
is used for analysis) allows the amount of genes in a 
network being partially retrieved. Importantly, a few 
malignant phenotypes as well as   prognostic factors are 
reflected by the gene components in the selected STAT3 
subnetworks indicating the important role of STAT3 in 
an ER(-) breast cancer population (Tables 1 and 3).Liu et al
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major clinical implications of STAT3 in 77 breast 
cancer gene expression profiles
STAT3 is a negative determinant of lymph nodal cate-
gory and of stage in ER(-) infiltrating ductal carcinoma 
of breast (Fig. 3). We selected those gene pools, which 
contain STAT3 and are relevant in two clinical indi-
ces, to find their shared gene cluster by Venn Diagram 
analysis (Fig. 4C). We observed that both ARNT (also 
known as HIF1B: the beta subunit of a heterodimeric 
transcription factors –HIF1 and HIF2) and MYC were 
two transcription factors in a STAT3 cluster for two 
clinical indices (Table S1.1). Only MYC but not ARNT 
was predicted to be a target gene of STAT3 transcrip-
tional regulatory network (Table S1.2) although there 
were at least 70   transcription factors and/or their sub-
units within this network. The inferred STAT3 target 
genes in clinically significant (CS) STAT3 transcrip-
tional regulatory network (4,418 probes) has broad 
effects on seven clinical categories typically in NP, 
LNM and stage (Data not shown). Only a few genes 
are also found in Warburg effect (IDH3G), metasta-
sis (BOP1, FOXC2 and MMP17) and angiogenesis 
(TYMP)(Table 3). Whereas transcription factor ARNT 
but no STAT3 was found to be in a MYC cluster for three 
clinical  indices  (Table  S1.3).  Interestingly,  a  MYC 
transcriptional  regulatory  network  shared  by  those 
three clinical indices predicted STAT3 to be a MYC 
target gene (Fig. 5B and Table S1.4). This   indicates 
Table 1. Significance in clinical outcomes for target genes 
in STAT3 & MYC overlapped network based on survival 
analyses on ER(-) IdCs (91A) or ER(-) BC (96A*) or 77 
ER(-) IdCs (77A#). The survival curve of IGF2, IGF2R, 
METAP2 and MMP7 in ER(-) BC can be seen in   Figs. 7C 
and S4.4.
Increased  
expression  
level
Gene symbol  
(Feature no.)
P value pathways
poor  
prognosis
IGF2 (21991) 0.009# Angiogenesis
poor  
prognosis
IGF2R (13825) 0.039 Angiogenesis
poor  
prognosis
mETAp2 (9356) 0.049*;  
0.025#
Angiogenesis 
and cell 
proliferation
poor  
prognosis
mmp7 (21090) 0.039;  
0.043*;  
0.039#
EmT and 
FoXC1 
network
notes: An asterisk (*) is for 96A which contain gene expression profiles 
for  91IdCs  and  5mCBs. A  symbol  (#)  is  for  77A  which  contain  gene 
expression profiles for 48TN and 29 ERBB2+.
Table 2. The pathological information (Clinicopathological 
parameters) for ERBB2+, triple negatives (TN) and meta-
plastic carcinoma of breast (mCB).
clinical index status number of patients
Tn eRBB2+ McB
ER 0 48 29 5
1 0 0 0
pR 0 48 29 4
1 0 0 1
HER 0 48 0 4
1 0 29 0
NA 0 0 1
Stage 1 13 4 0
2 26 13 4
3 and 4 9 12 1
NA 0 0 0
LYm 0 29 8 4
1 17 20 1
NA 2 1 0
LVI 0 24 8 2
1 23 14 0
NA 1 7 3
Age (years) ,48 12 9 0
.48 36 20 5
Grade 1 0 0 0
2 16 11 0
3 31 16 2
NA 1 2 3
TF 1 0 0 0
2 8 0 0
3 38 24 0
NA 2 5 5
Np 1 0 0 1
2 12 11 0
3 34 13 0
NA 2 5 4
mC 1 11 5 0
2 15 10 0
3 20 9 0
NA 2 5 4
Tumor size 1 16 5 0
2 25 17 2
3 6 7 3
NA 1 0 0
LNm 0 30 9 0
1 10 8 0
2 3 5 0
3 5 5 0
NA 0 2 5
both MYC and STAT3   mutually regulating each other 
(Fig. 5A). Therefore, we   hypothesized that clinical 
roles of STAT3 may be mainly the combined effect of 
MYC  and  STAT3    regardless  of  more  than  70  tran-
scription   factors being inferred target genes of STAT3 
(Table S1.2).malignant phenotypes regulated by STAT3
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MYC is known to be an oncogene.27 We observed   
aberrant  expressions  of  both  MYC  and  STAT3   
  predominantly in TN as compared to those in ERBB2+ 
(Fig. 3). Its pathological roles in TN are of our interest. 
We selectively investigated a STAT3 mediated tran-
scriptional regulatory network involving   co-regulation 
with MYC in TN during tumor progression. Many tran-
scription factors were statistically identified to be target 
genes of both MYC and STAT3 (Tables S1.4 & S1.5). 
Differential expressions of 268 probes were predicted 
to  be  significantly  regulated  by  MYC  and  STAT3. 
They are commonly found in three clinical indices 
(LNM, LVI and Stage) of 77 ER(-) IDCs (Fig. S3.8 
and Table S1.6). The potential pathological roles con-
tributed by this core network are summarized in a bar 
chart (Fig. 4E). Major clinical niches of this core net-
work fall into two categories (LNM, stage). In addi-
tion, we found LVI, NP, LYM, MC, grade, size, TF 
and age to be also determined by STAT3 in coupling 
with MYC, in part. Major gene activities of this core 
network (241/268) were found to be commonly sig-
nificant in TN subtype and relevant to those clinical 
categories except 27 probes (27/268) (Table S1.7 and 
Fig.  S3.8).  The  annotation  for  their  biological  and 
cancer related roles are in Table S1.7. Notably, both 
MMP17, STAT5a were predicted to be up-regulated by 
MYC and STAT3 (Fig. S3.8).   Membrane-type 4 matrix 
  metalloproteinase (MMP17) promotes breast cancer 
growth and metastases.28 Deregulated MYC expression 
up regulates a known antiapoptotic survival pathway 
in vivo involving   STAT5a.29 As such, those authors 
speculated that MYC may require activation of STAT5 
as a mechanism to avoid apoptosis in the processes of 
tumor initiation and progression. Other annotated gene 
functions in 268 probes (Table S1.6) should not be 
only limited as they are now because each gene prod-
uct may have more than one function to potentially 
predict its sum activities driven by MYC and STAT3 in 
relation to breast cancer development. Future studies 
will be needed to support our findings.
Hunting for malignant phenotypes indicated  
in STAT3 network in relation to multiple steps  
of tumorigenesis
We reasoned that STAT3 is mainly coupling with MYC 
to be involved in activities of tumorigenesis in STAT3 
network.  They  may  include  activities  documented 
from in vitro studies by others.
Firstly, we tested TN enriched MYC & STAT3 over-
lapped transcriptional regulatory network for their pre-
dicted gene activities in signal transduction pathways. 
Nine common signal transduction pathways (Fig. 4F 
and Tables S2.1–2.9) were tested to be regulated by 
both MYC and STAT3, in part. Genes within overlapped 
network of MYC & STAT3 in seven signal transduc-
tion  pathways  showed  their  expression  patterns  in 
heatmaps (Tables S3.1–S3.7). We determined the most 
relevant biochemical activities as the candidates for 
identification of malignant phenotypes enriched in TN.
In addition, we observed genes involved in epi-
thelial mesenchymal transition (EMT) and   Warburg 
effect  to  be  in  an  overlapped  network  of  MYC  & 
STAT3 ( Table  S1.5). As  a  result,  we  selected  four 
STAT3 subnetworks co-regulated by different combi-
nation of TFs (Figs. 5C–F). Those subnetworks and 
their corresponding dynamic changes during tumor 
development are presented in Figure 6. We concluded 
that four enriched activities are sustained angiogen-
esis, cell proliferation, EMT and Warburg effect. Two 
distinctive subnetworks were further illustrated along 
with their relevant clinical implications (Fig. 7).
Four functional subnetworks to be present 
in biochemical and/or malignant phenotypes 
enriched in TN
In  this  study,  only  five  metaplastic  carcinoma  of 
breast (MCBs) were available to be compared with 
Table 3. Up regulated cancer related genes in the over-
lapped network of clinically significant (CS) STAT3 or of 
CS MYC & STAT3 and their predicted phenotypes.
Features cancer related genes
Network CS STAT3 overlapped  
network and its gene  
subpools non- and  
overlapped with genes  
in LNm and/or stage
CS MYC 
& STAT3 
overlapped 
network 
(Fig. 4d)
Gene pool(s) 281probes (LNm enriched)  
or 233 probes (stage  
enriched) or 354 probes  
(LNm and stage enriched)
268 probes
Warburg effect IdH3G NA
metastasis FoXC2; Bop1;  
mmp17
mmp17; 
Bop1
Angiogenesis 
Anti-apoptotic 
activity
TYmp (ECGF1)  
NA
NA  
mYC & 
STAT5a
note: “NA”: data not available.Liu et al
94  Cancer Informatics 2012:11
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
P = 0.028
P = 0.767 P = 0.079 P = 0.267 P = 0.818 P = 0.794
P = 0.109 P = 0.128 P = 0.027 P = 0.097 P = 0.045
(48) (29)
3 23 2
(47) (27) (8) (62)
3 2
(23) (47)
(32) (37) (37) (39) (8) (10) (21) (17) (39) (21) (42) (13) (18) (37)
−+
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−+
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
−+ 1 3 2 0
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
1 3 and 4 3 and 4 2
(16) (56) (21)
< 48 > 48
(25) (29)
13 2
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
1 2
−
0
.
5
0
.
5
1
.
0
1
.
5
0
.
0
Age MC TF Grade
HERL VI LYML NM Tumor size Stage
NP
S
T
A
T
3
 
(
1
5
0
1
3
)
 
e
x
p
r
e
s
s
i
o
n
S
T
A
T
3
 
(
1
5
0
1
3
)
 
e
x
p
r
e
s
s
i
o
n
a. STAT3 (15013) in ER(−) IDCs (77A)
A
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−
0
.
5
−
1
.
0
0
.
5
1
.
0
1
.
5
0
.
0
−+ −+ −+ 13 2 01 3 and 43  and 4 21 2
HER LVIL YM LNMT umor size Stage
3 23 23 2 <48 >48 13 2
Age MC TF Grade NP
(47) (27) (8)( 62) (23) (47) (16) (56) (21) (25) (29)
P = 0.532 P = 0.062 P = 0.405 P = 0.741 P = 0.432
(48) (29) (32) (37) (37) (39) (8)( 10)( 21)( 17)( 39)( 21) (42) (13) (18) (37)
P = 0.103 P = 0.168 P = 0.262 P = 0.105 P = 0.436 P = 0.165
S
T
A
T
3
 
(
4
3
8
6
)
 
e
x
p
r
e
s
s
i
o
n
S
T
A
T
3
 
(
4
3
8
6
)
 
e
x
p
r
e
s
s
i
o
n
b.STAT3 (4386) in ER(−) IDCs (77A)
Figure 3. (Continued)malignant phenotypes regulated by STAT3
Cancer Informatics 2012:11  95
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
−
2
.
0
−
1
.
0
0
.
5
0
.
0
3 23 2
(47) (27) (8)( 62)
3 2
(23) (47) (16) (56) (21)
< 48 > 48
(25) (29)
13 2
Age MC TF Grade NP
P = 0.004 P = 0.813 P = 0.947 P = 0.198 P = 0.981 P = 0.338
(48) (29) (32) (37) (37) (39) (8)( 10)( 21) (17)( 39)( 21) (42) (13) (18) (37)
−+ −+ −+ 1 3 2 01 3 and 43  and 4 21 2
HER LVI LYM LNM Tumor size Stage
P = 0.921 P = 0.213 P = 0.964 P = 0.127 P = 0.583
M
Y
C
 
(
1
8
0
7
)
 
e
x
p
r
e
s
s
i
o
n
M
Y
C
(
1
8
0
7
)
 
e
x
p
r
e
s
s
i
o
n
a. MYC (1807) in ER(−) IDCs (77A)
B
Figure 3. Upper panel, univariate analyses of STAT3 mRNA levels on seven clinical indices—HER, LVI, lymph nodal category (LYm, LNm), age, tumor 
size, grade (Nuclear pleomorphism, mitotic count, Tubule formation) and stage in ER(-) IdCs (A). Two transcript variants (A_a, A_b) are analyzed. Lower 
panel, univariate analyses of MYC mRNA levels on seven clinical indices in ER(-) IdCs (B). Two transcript variants (B_a, B_b) are analyzed.
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two    subtypes  of  ER(-)  IDCs  by  their  heatmaps 
although a large number samples will be needed for 
future validation. Five MCBs16 are triple negatives 
(Table 2) and were included to test if MYC & STAT3 
regulatory activities are shared among ER(-) breast 
cancer subtypes.
A metabolic transcriptome involving STAT3 network
Warburg effect in ER(-) IDCs was mainly due to 
MYC directed transcriptional up regulation on PC, 
OGDH, GLS, LDHB and IDH3G that was predicted 
by MYC transcriptional regulatory network. Only PC, 
OGDH and IDH3G were predicted to be co-regulated 
5 0 0 10 10 15 20 20 25 50 50 30 30 45 40 40 35
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clinical indices in 268 probes
Numbers of probes for signal transduction path-
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D
Figure 4. Examples of ERBB2 status determined by results of both CISH (left side picture) and IHC (right side picture) in (A) and (B). Two Venn diagrams 
represent the key results from hunting for the main components of STAT3 network. (c) is for gene pools significantly associated with 2 clinical indices 
(including STAT3, MYC, and ARNT) that include their non- and overlapped genes. (D) is for target gene pools of both MYC and STAT3 networks that 
are also clinically significant (CS) including their non- and overlapped genes. (e) is a bar chart of probe number within 268 probes to be overlapped with 
probes in ten clinicopathological parameters, respectively. (F) is a bar chart of probe number within 6,606 probes, which are in MYC and STAT3 overlapped 
network, for their probes overlapped with probes in nine assigned signal transduction pathways, respectively.malignant phenotypes regulated by STAT3
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Figure 5. Functional analyses on STAT3 gene partners in TN via (1) predicted subnetworks derived from genes in STAT3 & MYC overlapped network in 
both TN and ERBB2+ breast cancer gene expression profiles (A) and key genes in MYC core network of three clinical indices (B); (2) Feature functional-
ities of major target genes for STAT3 in two STAT3 subnetworks (sustained angiogenesis and cell proliferation) are either commonly co-regulated by MYC 
and/or differentially co-regulated by FOXM1 or ARNT (c). Those in a STAT3 subnetwork for Warburg effect are co-regulated by ESRRG (D). A subset 
of genes regulated by multiple combined routes of MYC & STAT3, FOXM1 & STAT3, ARNT/HIF1A & STAT3, ARNT/HIF2A & STAT3 or STAT3 for ES 
like phenotype (e). A FOXC1 subnetwork (F) is a part of activities for cell proliferation and EMT. Majority components of this subnetwork are significantly 
associated with mitotic counts.
notes: Solid/dashed lines stand for specific pathway identified as significant/insignificant in gene expression relationship between a TF and a target gene. 
Each arrow points to its downstream target and only the combined routes toward the same target gene are labeled with the same color.Liu et al
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by STAT3 (Figs. 5D and 6B). In TN enriched MYC 
network, GLS and LDHB were predicted to be down-
regulated by ESRRG and to be ESRRG target genes. 
No significant tumor suppressive event predicted to 
be regulated by ESRRG was found except that down 
regulation  of  LDHB  may  decrease  mitotic  counts 
(Fig.  6D  and  Table  S4.1)  in  ER(-)  breast  cancer. 
  Interestingly, LDHB was up-regulated in non-tumor 
part which may suggest its physiological role. In addi-
tion, ESRRG may up regulate HK1 in ERBB2+ that 
is a determinant of LVI and of tumor size (Table S4.1 
and Fig. 5D). We observed that MCBs show similar 
gene expression patterns for Warburg effect as com-
pared to TNs (Fig. 6B).
phenotype like mesenchymal stem cells in tumor 
pathogenesis involving action of STAT3 network
Both MYC and STAT3 have been identified to con-
tribute in Stemness.30 In triple negatives, we observed 
up-regulating expressions of TWIST1, SNAI1, FOXC1 
and FOXC2, in the overlapped network driven by MYC 
and STAT3 to suggest some of EMT gene   activities. 
Part of their roles is known as   epithelial repressing TFs 
or mesenchymal activating TFs.31 After clinicopatho-
logical  characterization  of  those  subnetworks,  we 
immediately observed FOXC1 to be heavily involved 
in cell proliferation and MELK related proliferative 
activities (Figs. 5C, F, 6C, D, Table S4.1). MELK is 
a  determinant  of  histological  grade  and  of  mitotic 
count in ER(-) IDCs (Table S4.1). MELK has been 
documented to be up-regulated during mammary car-
cinogenesis, a poor prognostic factor of breast cancer 
and a promising therapeutic target for multiple can-
cers.32–35 Many transcription factors besides FOXC1 
in MYC & STAT3 overlapped network are also deter-
minants of mitotic count (Table S4.1). In addition, it 
predicted KLF4 and NOTCH1 to be up-regulated pre-
dominantly in TN via MYC and STAT3 co-regulation. 
This suggests that some of ES like phenotype ruled 
by MYC & STAT3 transcriptional regulation(s) may 
increase the invasiveness of TN. On the other hand, 
the counter parts of TN tumor specimens also express 
some of those transcription factors (the pluripotent 
factors) supporting the finding for breast stem/progen-
itor cell markers in both normal and tumor samples.36 
Those gene   activities of TWIST1 and SNAI1 in normal   
Proliferation (part of network 5C)
Sustained angiogenesis (part of network 5C)
Warburg effect (network 5D) B
C ES like (network 5E)
A
MC (part of networks 5C-F)
Grade (part of networks 5C-F)
Part of FOXC1 network (network 5F in G2 vs. G3)
D Part of FOXC1 network (network 5F in MC1 vs. MC3)
0.79 0.45 0.26 0.12 0 −0.11 −0.24 −0.41 −0.7
Figure 6. Heatmaps for subnetworks of MYC & STAT3 differentially coupling with ARNT, FOXM1 in different clinical indices and subtypes of breast cancer. 
Non-tumor part (NT) serves as a control. Unsupervised gene expression patterns were clustered for subnetworks of three altered biological events (A, B, 
and c). Networks of MYC & STAT3 in coupling with other transcription factors as well as a FOXC1 subnetwork are observed to functionally promote grade 
development (D) and sustained angiogenesis (A). The color bar underneath of the heatmap shows beige color for earlier pathological status and light 
blue color for later pathological status of each denoted clinical index. For instance, at right panel of Figure 6 shows heatmaps for part of FOXC1 network, 
subnetworks in Figs.5C-F. At lower panel of Figure 6A, the color bar underneath the heatmaps indicates patients with differential activities of sustained 
angiogenesis to be not related to their LNm status.
notes: “G2”, “G3” stand for histological grade 2, 3, respectively. “mC1”, “mC3” stand for mitotic count 1, 3, respectively.malignant phenotypes regulated by STAT3
Cancer Informatics 2012:11  99
05 10 15
Time to death (years)
TN (48)
ERBB2+ (29)
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
P = 0.301 P = 0.904
E. Survival curves (TN vs. ERBB2+)
024681 01 2
Time to death (years)
Subcohort 1 (31)
Subcohort 2 (7)
F. 
5
4
3
5
5
4
1
7
5
4
3
3
4
3
9
9
5
3
1
7
4
3
8
9
4
3
5
5
5
3
2
3
4
3
7
7
1
7
1
5
5
3
4
3
1
3
5
5
5
4
0
1
4
4
1
5
4
4
1
9
4
4
1
7
5
3
5
7
5
3
0
5
1
6
6
5
2
4
6
3
5
3
3
5
5
3
0
1
5
3
5
9
5
8
8
9
5
3
7
3
5
3
9
5
5
3
8
5
5
3
6
3
5
3
3
7
1
4
3
3
4
4
2
1
5
3
2
9
5
3
3
3
5
3
3
9
5
3
8
7
5
3
7
5
5
3
4
1
2
4
6
9
1
7
1
1
1
7
6
3
4
3
5
7
1
7
7
9
1
6
8
1
4
3
7
5
4
3
8
7
4
4
0
3
1
4
5
3
5
3
9
3
4
4
1
3
4
4
0
7
4
4
3
1
4
4
0
9
4
3
9
5
4
3
9
3
4
3
8
3
5
3
4
5
4
3
9
7
5
3
2
5
4
3
6
9
4
3
6
7
4
3
7
3
4
3
6
5
5
3
0
7
4
3
6
3
1
6
5
7
4
4
1
1
4
3
6
1
1
6
6
1
4
3
7
1
4
4
0
5
5
3
9
9
4
3
5
3
5
3
2
7
2
4
6
1
1
6
8
3
5
3
1
9
4
4
0
1
5
3
2
1
4
3
7
9
4
3
5
9
4
3
8
5
1
6
2
1
4
3
9
1
5
3
4
7
4
3
8
1
5
4
3
7
5
4
2
7
5
4
0
9
1
5
9
1
D FOXC1 subnetwork
NT TN MCB ERBB2+
TIPRL
DEX
KLF5 
ELF5
E2F8
MELK
OIP5
BIRC5
TCF7L1
MMP7
BATF2
STAT3
STAT3
MYC
MTA1
MTA1
MYC
FOXC1
BIK
BIK
SPDEF
ZFHX3
XBP1
SP5
AR
FOXA1
05 10 15
Time to death (years)
0
.
0
0
.
2
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
0
.
4
1
.
0
0
.
8
0
.
6
P = 0.025
High (8)
Low (69)
METAP2(9356) mRNA expression
2 1 2 1
TN enriched High Low
VEGFC
VEGFA
METAP2
METAP2
VEGFC
VEGFA
STAT3 STAT3
PGF
MYC ARNT ARNT ARNT ARNT MYC
PGF
Sustained angiogenesis is mainly following both VEGF and PDGFRB sig-
naling pathways during disease progression. Dynamic regulatory switches
among ARNT/EPAS1 (HIF2) & STAT3 networks, ARNT/ HIF1A (HIF1) &
STAT3 networks and PDGFRB (MYC & STAT3) networks are hypothesized. 
B
a. TN (ID 5321) V+ b. TN (ID 4369) V– c. ERBB2+ (ID 5335) V+ d. ERBB2+ (ID 5363) V+
−0.70 .79 0.45 0.26 0.12 0 −0.11 −0.24 −0.41
A Sustained angiogenesis
NT TN MCB ERBB2+
PGF
ABL1
EPAS1
PDGFB
ARNT
SRC
IGF2
STAT3
STAT3
MYC
MYC
AKT2
CSK
PDGFRB
LYN
VEGFC
EPAS1
METAP2
IGF2R
IGF2R
AKT1
VEGFA
VEGFA
1
5
9
1
5
4
0
9
4
3
6
9
4
3
5
7
5
3
5
9
4
4
1
9
4
4
1
7
4
4
1
5
5
8
8
9
5
3
5
7
2
4
6
3
5
3
2
9
1
3
5
5
5
3
3
3
5
3
7
5
4
4
2
1
5
3
3
7
1
4
3
3
5
3
8
5
5
3
6
3
5
3
9
5
5
3
7
3
5
3
8
7
5
3
0
5
5
3
0
1
5
3
3
9
5
3
4
3
5
3
4
1
2
4
6
9
5
4
0
1
1
7
1
1
1
6
6
5
5
3
3
5
1
7
1
5
1
6
8
1
1
7
6
3
1
7
7
9
5
3
1
7
5
3
2
1
5
3
4
5
5
3
2
3
1
6
5
7
5
3
0
7
4
4
0
1
4
3
8
5
1
6
6
1
1
6
2
1
5
3
4
7
4
3
8
3
4
3
7
3
4
3
7
9
4
3
5
9
5
3
1
9
4
3
9
9
4
3
6
5
4
3
8
9
4
3
9
1
4
3
7
1
4
3
8
1
4
3
7
7
4
3
9
7
4
3
6
7
4
3
9
5
4
3
9
3
4
3
6
3
4
4
1
1
4
4
0
3
5
3
2
5
4
4
1
3
4
4
0
9
1
4
5
3
4
4
3
1
4
3
8
7
4
3
7
5
4
4
0
5
4
3
6
1
5
3
2
7
2
4
6
1
4
3
5
3
4
4
0
7
1
6
8
3
4
3
5
5
5
3
9
9
5
3
9
3
5
4
3
7
5
4
2
7
5
4
3
5
5
4
3
3
5
4
1
7
C
Survival curves (FOXC1 subnetwork (31 (+) vs. 7 (−))
Figure 7. Further evaluation on two novel gene sets predicted to be involved in tumor angiogenesis and mitotic count promotion, respectively. Two 
  heatmaps are displayed for subnetworks of MYC & STAT3 differentially coupling with ARNT/HIF1A, ARNT/HIF2A, and FOXC1 in three subtypes of 
breast cancer (TN, mCB, and ERBB2+) (A, B, and D). Their related clinicopathological phenotype- vascularity (a-d) and prognostic features (c, e, and 
F) are demonstrated. Non-tumor part (NT) is the control. Upper panel shows at least two transcriptional regulatory networks interacting with the center 
regulator-STAT3 in co-regulating sustained angiogenesis. We pulled genes together based on their activities shared with two signal transduction pathways 
(i.e. VEGF and pdGFRB in Fig. 4F). Those gene expression levels are shown in the heatmaps (A). A series of in vivo sonographic images (a-d) show that 
tumor vascularity would validate the predicted gene activities shown on the heatmaps (A) for two subtypes (TN and ERBB2+) of ER(-) IdCs. dissecting 
those gene activities driven differentially by at least two transcriptional regulatory networks, one diagram of this hypothesis is shown in (B). METAP2 is 
a component of sustained angiogenesis and is predicted to be a poor prognostic factor (c). “V+” stands for positive vascularity. “V-” stands for negative 
vascularity. “1” stands for HIF1. “2” stands for HIF2. Lower panel shows a FOXC1 transcriptional regulatory subnetwork enriched in TN but not significant 
in prognosis. The heatmaps show mRNA levels of probes in FOXC1 subnetwork enriched in TN (D). The subtypic difference between TN and ERBB2+ in 
their survival probability after surgical removal of tumor is not significant (e). A subset of patients with high activity of FOXC1 subnetwork (subcohort 1) is 
not significant to be a predictor for poor prognosis in TN when it is compared with low activity one (subcohort 3) (F).Liu et al
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development of the ductal network during mammary 
gland development as well as in promoting distance 
metastasis  for  breast  cancer  progression  have  been 
documented.37
Other published data showed that HIF1 and HIF2 
actively induced EMT event via coupling with the 
existing  STAT3  in  tumor  setting.38  It  supported 
the prediction shown in Figure 5E. Typically, they 
found  that  HIF2  a  correlates  with  distant  recur-
rence and poor outcome in invasive breast cancer.38 
  However,  no  significant  findings  for  the  potential 
role of HIF2 a (EPAS1) based on this study (Table 
S4.1). We observed high expression level of HIF2 a 
mRNA in the heatmap of tumor adjacent counterpart 
(Fig. 6C), although all the current research evidence 
by others suggested no critical role for HIF2 a dur-
ing mammary gland development. Its protein level 
is undetectable in some non-tumor part.39 Therefore, 
our finding on a relatively high mRNA expression 
level  of  HIF2  a  in  non-tumor  samples  deserves 
future study in a large cohort. For this subnetwork, 
MCBs show similar gene expression pattern with a 
subset of TN and ERBB2+ (Fig. 6C).
Increased tumor survival mechanism via  
sustained angiogenesis involving STAT3
We hypothesized a pathway for sustained angiogen-
esis, which is proved to be significant in the over-
lapped network of MYC & STAT3. Fig. 5C shows 
that it includes the IGF2-IGF2R-PLC_2 axis40 and 
VEGF  signaling  (KEGG  database).  Based  on  net-
work approach and signal pathway profiling, it infers 
both HIF1 and HIF2 interacting with STAT3 to lead 
a  functional  transcriptome  mainly  consisting  of 
METAP2 and VEGFC possibly for sustained angio-
genesis. VEGFA is a direct target gene of HIF141 and 
STAT3.42 In the meantime, we observed both MYC and 
STAT3 networks that may rule both VEGF and PDG-
FRB signal transduction pathways to sustain angio-
genesis during ER(-) breast tumor development. The 
cross talking between two pathways for the sustained 
angiogenesis is via STAT3 (Fig. 7B).
The  activation  of  PDGFRB  signal  transduction 
pathway has been documented43 during lymphangio-
genesis  involving  activity  of  VEGFC.  It  involves 
STAT3-mediated MYC expression for Src transforma-
tion and PDGF-induced mitogenesis.44 We observed 
the predicted actions of ARNT in regulating PDG-
FRB, VEGFC and VEGFA during stage   progression. 
In addition, METAP2 is within STAT3 & ARNT over-
lapped network and were predicted to be regulated 
during LVI progression (Data not shown). We also 
found that c-Src mRNA expression was associated 
with LVI in ER(-) IDCs (Table S4.1). C-Src is acti-
vated  by  METAP245  that  allows  the  activation  of 
STAT3 to functionally regulate STAT3 network (see 
the mechanism in a paragraph below). We, therefore, 
hypothesized  that  other  transcriptional  regulatory 
pathways,  such  as  HIF1/STAT3  and  HIF2/STAT3, 
may  control  in  expressions  of  VEGFA,  VEGFC 
and METAP2 during tumor angiogenesis in ER(-) 
population.
In the meantime, we observed from the heatmaps 
(Figs. 7A and S3.6) that the non-tumor part showed 
relatively low expressions of genes in PDGFRB sig-
naling pathway, suggesting that it may slightly par-
ticipate in VEGFC induced vascularity as well as in 
constitutive  activity  of  METAP2  for  physiological 
states in non-tumor part of breast tissue. Further com-
parison on the relative mRNA levels of a few key 
angiogenesis related genes in box plots (Fig. S4.3) 
revealed difference among TN, ERBB2+ and non-
  tumor part. MCBs appear to have sustained angio-
genesis  and  their  gene  expression  patterns  are 
similar to subsets of patients in both TN and ERBB2+ 
(Fig. 7A).
Based on the hypothesis shown in Figure 7B, we 
suspected that blocking the activities of METAP2 will 
indirectly inhibit angiogenesis in ER(-) IDCs. The 
supporting data by others are (1) C-Src is activated 
by METAP2 that is involved in the cotranslational 
removal  of  protein  initiator  methionine  of  c-Src45; 
(2) Functional c-Src is found to activate transcrip-
tional activity of STAT3 via tyrosine phosphorylation 
on Y70545; (3) Both VEGFA and VEGFC are target 
genes of STAT3.46,47 Together, we proposed that the 
inhibitory mechanism on angiogenesis by targeting 
METAP2 may be not only through c-Src but through 
other molecules which are activated via translational 
and posttranslational regulation by this bifunctional 
protein—METAP2/eIF2 alpha binding protein.48,49
Tumor proliferative activities regulated by network  
of STAT3 and/or that of other TF(s)
Dynamic changes in expressions of a few candidate 
biomarkers  are  mediated  by  STAT3  during  tumor malignant phenotypes regulated by STAT3
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development. We found that inappropriate expression 
and activation of STAT3 lead to pathogenesis at early 
stage of disease progression. As a consequence of 
STAT3 action, one of its target genes—FOXC1 deter-
mines part of cell proliferation during grade promo-
tion typically shown in tubule formation (Table S4.1). 
On the other hand, mRNA expression of METAP2 
is  predicted  to  be  suppressed  by  MYC  and  STAT3 
(Fig. 5C). It may suggest its proliferative activity50 
to be at relatively late stage of tumor development. 
Interestingly, METAP2 is the determinants of stage, 
LYM, LVI, NP and tumor size (Table S4.1). Other 
line of research evidence suggested METAP2 to be an 
oncogene50 that supports our findings. Both FOXC1 
and  FOXM1  are  two  gene  partners  of  STAT3  for 
grade development. This is a TN enriched event. We 
observed MELK to be up-regulated by both FOXM1 
and FOXC1, respectively (Fig. 5C). MELK is a grade 
determinant. Both MELK and DEK are determinants 
for mitotic counts (Fig. 6D) in ER(-) IDCs suggest-
ing FOXC1 network interacting with FOXM1 net-
work for uncontrolled proliferative activities. MCB 
shares the gene expression patterns with TN and a 
subset of ERBB2+ (Fig. 6D and part of Fig. 6A). The 
role of up-regulated DEK in non-tumor part deserves 
further investigation in a larger sample size. FOXC1, 
MELK and DEK are known as markers for poor prog-
nosis.25,33,51,52 Gefitinib is known to suppress FOXM1 
expression.53  Moreover,  FOXC1,  MELK  and  DEK 
may be candidates of druggable targets for anticancer 
treatments of subsets of TN, MCB and ERBB2+.
Validation of major functional MYC & STAT3 
subnetworks in TN and ERBB2+
The  STAT3  network  predicted  STAT3,  METAP2, 
VEGFA and FOXM1 to be druggable targets for treating 
subsets of TN, MCB and ERBB2+ patients (Figs. 5A 
and C). A few transcription factors are within multi-
ple routes of transcriptional regulation on their target 
genes via interacting with STAT3. They significantly 
take part in building up not only some biochemical 
phenotypes (Fig. 4F) but a few morphological phe-
notypes (Figs. 5, 6 and 7) for subsets of patients in 
both TN and ERBB2+. Each protein encoded by a 
target gene of STAT3 may have multiple functions 
and its clinical impacts may just start to be unrav-
eled through connecting with the functional transcrip-
tomes of those major transcription factors via network 
approach. We predicted their functions in vivo by their 
gene annotations, pathway profiling and their aberrant 
expression during tumor development.
We were able to validate those statistically predicted 
transcriptome within STAT3 network in relation to sus-
tained angiogenesis in vivo (Fig. 7A). We examined the 
color Doppler vascularity and mRNA expressions of 
angiogenesis-related molecules within MYC & STAT3 
networks of each patient (see the heatmaps in Fig. 7A). 
As a result, those patients whose breast tumors expressed 
a transcriptome coding for proteins in sustained angio-
genesis were detected to be positive in vascularity (see 
angiosonograms in Fig. 7a, c and d). Figure 7b has 
invisible vascularity but having high VEGFA mRNA 
expression  that  suggests  tumor  vascularity  of  that 
patient to be below the sensitivity limit of color Doppler 
ultrasound. We further evaluated the prognostic power 
of those genes (see Fig. 7C) within functional MYC & 
STAT3 overlapped network in ER(-) breast cancer pop-
ulations (77A, 91A or 96A). High level of METAP2 
mRNA expression is an independent prognostic factor 
associated to reduced breast cancer–specific survival in 
ER(-) population (P = 0.049, 96A; P = 0.025, 77A). 
So are to MMP7 mRNA expression (P = 0.039, 91A; 
P = 0.039, 77A), IGF2R mRNA expression (P = 0.039, 
91A) and IGF mRNA expression (P = 0.009, 77A) 
(Table 1 and Fig. S4.4).
dynamical changes of network  
activities mediated by STAT3 and  
MYC enriched in TN
MYC & STAT3 overlapped network is known heavily 
involved in both stem cell and breast cancer devel-
opment. Both MYC and STAT3 are master TFs. We 
observed that they have broad spectrum effects on 
tumor development due to numerous TFs to be their 
gene  partners  in  each  individual  network  (Tables 
S1.1–S1.7). For instance, we observed a set of TFs 
differentially expressed in MYC network and some 
are  clinicopathological  determinants  (Fig.  5B  and 
Table S4.1). There are multiple transcription factors 
within MYC & STAT3 overlapped network. As such, 
the oncogenic activities of this network in contrib-
uting to clinicopathological categories will provide 
functional links between gene pools and their poten-
tial niches in breast cancer development.
In reality, the transcriptional regulatory network 
approach is beyond the scale of individual TF alone Liu et al
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but involving more interactions among TFs. We did 
identify four oncogenic activities—Warburg effect, 
EMT, cell proliferation and angiogenesis based on 
their gene profiles predicted to be driven by a few 
combined  co-regulatory  events  among  five  major 
TFs—MYC,  STAT3,  ARNT/HIF1a,  ARNT/HIF2a 
and FOXM1. Therefore, multivariate portion of its 
network should play important role in interpreting 
causal mechanisms for their downstream gene pools. 
More druggable targets are expected to be discovered 
in this study. An established STAT3 transcriptional 
regulatory network indicates STAT3 to be a center 
regulator in ER(-) breast cancer.
This approach is promising because one of sub-
network  activities—sustained  angiogenesis  was 
validated  by  angiosonograms  (Figs.  7A–D).  The 
annotated gene functions within the predicted sub-
network  were  linked  to  functional  signal  pathway 
profiling (Fig. 4F). Gene expression patterns within 
MYC & STAT3 overlapped network indicate that two 
transcriptional regulatory pathways involving STAT3 
may  be  all  toward  sustained  angiogenesis  demon-
strated in Figure 7B. It suggests a hypothesis of cross 
talking between two possible signaling pathways that 
may promote tumor angiogenesis. For those patients 
with that signature subnetwork, they may have sup-
pressed local metastasis indicated by a clinicopatho-
logical category—LNM (see both STAT3 and MYC 
actions on LNM indicated in Fig. 3 and Table S4.1). 
Importantly, FOXC1 is predicted to be one of STAT3 & 
MYC shared target genes. FOXC1 core network may 
serve as a poor prognostic signature. We found 10 
probes (10/14) within FOXC1 network to be prefer-
entially up-regulated in TN (Figs. S4.1 and S4.2) and 
several of them were previously implicated to be poor 
prognostic factors by others.25,33,51,52 However, we can 
not prove our prediction based on network result (see 
Fig. 7F). We suspect that it may be because major-
ity of the cohort was recruited around 4-6 years ago 
(The breast tumor sampling was performed mainly in 
2005–2007) and the subcohorts for this prediction are 
small (total N = 38) in this study. FOXC1 is a low risk 
factor which was predicted to be a poor prognostic 
factor by survival analysis (for patients with .2 years 
after surgically removal of breast tumors).25 Lastly, 
elevated MYC and some of its target genes lead to 
Warburg effect are enriched in TN (Fig. 5D) that has 
been predicted by network approach. The most recent 
in vivo evidence supports our prediction that MYC 
up regulates a subset of gene expressions involved in 
Warburg effect in TN.54
conclusion
STAT3 appears to be a center regulator mainly in early 
development of an ER(-) breast cancer model system 
based on our network prediction. STAT3 is known to 
be a proto-oncogene and a multifunctional protein. In 
this hypothesis testing study, we concluded not only 
more than 70 transcription factors are potentially regu-
lated by STAT3 (Table S1.2) but total four functional 
subnetwork activities to be enriched in TN that are 
part of STAT3 network activities (Figs. 5C–F).
Major  findings  based  on  network  approach  are: 
(1) The subtype enriched gene activities revealed due 
to  both  MYC  and  STAT3  predominantly  being  up- 
regulated in TN. A subset of gene pool shared by reg-
ulatory networks of both MYC and STAT3 was found 
to participate, in part, in maintaining stem cell pheno-
type, cell proliferation, Warburg effect and sustained 
  angiogenesis. This indicates that STAT3 may also initi-
ate cancer metastasis through three major mechanisms: 
promotion of sustained angiogenesis (Figs. 5C, 6A, and 
7A), induction of tumor cell epithelial-mesenchymal 
transition (EMT) (Figs. 5E, 6C, D and Table 3), and 
activation/induction  of  proteolytic  enzyme  mediat-
ing tumor cell invasiveness (e.g. MMP7 in Fig. 5F; 
MMP17 in Table S1.6 and Fig. S3.8); (2) Both MYC 
and STAT3 are also relevant determinants to a few 
clinical indices (Fig. 3); (3) The predicted feedback 
regulatory action between MYC and STAT3 (Fig. 5A) 
enriched in TN indicates both networks to be mutually 
cooperative.  Evidence  on  common  gene  activities 
governing  a  range  of  clinical  indices  is  within  the 
core network co-driven by MYC and STAT3 (Fig. 4E). 
Notably, MMP17, BOP1 and STAT5a were predicted 
to be up regulated by both MYC and STAT3 in a sub-
set of patients that indicates the promotion on metas-
tasis, anti-apoptosis, respectively (Tables 3 and S1.6, 
Fig. S3.8). Moreover, STAT3 may be a key transcrip-
tion factor in ER(-) BC. MYC, FOXM1, ARNT/HIF1a 
and ARNT/HIF2a are predicted to be its major part-
ners to differentially regulate proliferation, Warburg 
effect, angiogenesis and ES like phenotype.
Novel findings based on STAT3 network should 
be not limited by (a) four poor prognostic factors- 
MMP7,  IGF2,  IGF2R,  and  METAP2;  (b)  four malignant phenotypes regulated by STAT3
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  druggable    targets-  VEGFA,  STAT3,  FOXM1  and 
METAP2; (c) clinical relevant; (d) subtype enriched. 
The summary for predicted clinical roles of com-
ponents in those subnetworks (Fig. 5F) and in core 
network of MYC (Fig. 5B) suggests that the clinical 
implications of STAT3 should be not limited to LNM 
and stage (Fig. 3) but should be extended to other 
clinical indices when this center regulator interacts 
with different partner transcription factor(s) that may 
cooperate with STAT3 to determine tumor cell fate 
predominantly in TN. Many downstream transcrip-
tion  factors  in  STAT3  network  may  have  interac-
tions with STAT3 and MYC in ER(-) breast cancer 
to be mostly unexplored before. Further dissecting 
the roles of STAT3 by building multivariate space of 
STAT3 mediated transcriptional regulatory network 
would  advance  our  understanding  for  this  master 
transcription factor in ER(-) BC.
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supplementary Data
A  combined  PDF  file  has  included  the  follow-
ing  contents except supplementary file 3 displayed 
below:
Table  of  content—a  PDF  file  contains  a  brief 
description for supplementary files.
  Supplementary file 1—a PDF file contains Tables 
S1.1–S1.7. 
  Supplementary file 2—a PDF file contains Tables 
S2.1–S2.9. 
  Supplementary file 4—a PDF file contains Table 
S4.1 and Figures S4.1–S4.4.
The following data (i.e. supplementary file 3) 
further interprets part of results in supplementary 
file 2. Here, we would like to illustrate that the same 
signal transduction pathway in different subtypes 
Figure s3.1. Heatmaps for eight probes in Table S2.4 and four probes for both MYC & STAT3. A subset of gene expressions in the mismatch repair 
pathway (MRP) shows lower mRNA levels in non-tumor part than in tumor part. The fluctuation of gene expression pattern indicates majority of patients in 
ER(-) population (many patients in TN and mCB but a small subset patients in ERBB2+) having altered mRp activity driven by MYC & STAT3.
Figure s3.2. Heatmaps for eleven probes in Table S2.2. A subset of gene expressions in dNA replication signal transduction pathway (dRS) shows lower 
mRNA levels in non-tumor part than in tumor part. Higher activity of dRS is indicated in both TN and mCB than in ERBB2+. Those genes are components 
within MYC & STAT3 overlapped network.
of  breast  cancer  as  well  as  non-tumor  part  has 
differential gene expression patterns due to a per-
turbed network driven by MYC & STAT3 enriched 
in the tumor compartment. The phenotypic changes 
are expected mainly for promoting tumor develop-
ment by MYC & STAT3 overlapped transcriptional 
regulatory network. To evaluate those critical genes 
in a perturbed network, we examined differentially 
expressed  network  components  in  the  heatmaps 
for  seven  signal  transduction  pathways.  In  addi-
tion, we demonstrated a core network of MYC & 
STAT3, which is TN enriched and clinicopathologi-
cally relevant, via the heatmap display in Figure 
S3.8. NT stands for non-tumor part. TN stands for 
triple negatives. MCB stands for metaplastic car-
cinoma of breast. ERBB2+ stands for ER(-)PR(-)
HER2/neu(+).malignant phenotypes regulated by STAT3
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Figure s3.3. Heatmaps for nineteen probes in Table S2.5. A subset of gene expressions in the nucleotide excision repair pathway (NER) shows different 
patterns in non-tumor part as compared to those in tumor part. NER is a common event in both non-tumor and tumor parts. However, both TN and mCB 
indicate more altered gene activities driven by MYC & STAT3 as compared to ERBB2+. No subtype specific gene expression pattern is observed.
Figure s3.4. Heatmaps for twenty five probes in Table S2.6. p53 signaling is known to be involved in tumor suppressive activity. TN, mCB and ERBB2+ 
are known to have high frequency of p53 mutation. As a result, the gene expression pattern of 25 probes in non-tumor part is distinctive. majority of TN, 
mCB and a small subset of ERBB2+ show in their gene expression patterns of 25 probes to be very different from non-tumor part. Such dramatical differ-
ence in a subset of gene expression patterns driven by MYC & STAT3 suggesting altered tumor suppressive activities of p53 signal transduction pathway 
in tumor part.Liu et al
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Figure s3.5. Heatmaps for twenty six probes in Table S2.7. A subset of gene expressions in vascular endothelial growth factor (VEGF) signal transduction 
pathway shows lower mRNA levels in non-tumor part than in tumor part. MYC & STAT3 networks may activate VEGF signal transduction pathway more 
in both TN and mCB populations but less in ERBB2+ population.
Figure s3.6. Heatmaps for thirty three probes in Table S2.9. We observed pdGFRB signaling with different driving force between non-tumor part and 
tumor part. For instance, aberrant gene expressions of MYC & STAT3 in tumor part would suggest more activity of this pathway that may contribute to 
selective tumorigenesis. more patients in TN as compared to those in ERBB2+ have up-regulated MYC & STAT3. mCB shares similar gene expression 
patterns with TN and a subset of ERBB2+. more mitogenic activity may be expected to contribute uncontrolled growth in tumor part because the target 
gene expression patterns (thirty three probes) within MYC & STAT3 overlapped network indicate increased survival from carcinogenesis and promoting 
tumor progression (please see the main text).malignant phenotypes regulated by STAT3
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Figure s3.7. Heatmaps for forty four probes in Table S2.8 and four probes for both MYC & STAT3. The phenotypic changes in ER(-) breast cancers due 
to cell cycle signal transduction pathway are expected mainly for promoting uncontrolled growth by MYC & STAT3 overlapped transcriptional regulatory 
network. We suspect this pathway to be regulated by MYC & STAT3 during tumor development of ER(-) breast cancers. For instance, CCNB1 involves in 
mitotic count. PTGG1, MAD2 L1 and CHEK1 are determinants for both grade and mC, while PKMYT1 is a determinant for Np in ER(-) IdCs.Liu et al
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Figure s3.8. Heatmaps for (A) twenty seven probes and (B) two hundred forty one probes in Table S1.7.publish with Libertas Academica and 
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